MASLD: a systemic metabolic disorder with cardiovascular and malignant complications
By G. Targher, Christopher D. Byrne, Herbert Tilg. Gut, 2024
738 citations recorded by the source corpus.
Non-alcoholic fatty liver disease (NAFLD) has rapidly become the most common chronic liver disease globally and is currently estimated to affect up to 38% of the global adult population. NAFLD is a multisystem disease where systemic insulin resistance and related metabolic dysfunction play a pathogenic role in the development of NAFLD and its most relevant liver-related morbidities (cirrhosis, liver failure and hepatocellular carcinoma) and extrahepatic complications, such as cardiovascular disease (CVD), type 2 diabetes mellitus, chronic kidney disease, and certain types of extrahepatic cancers. In 2023, three large multinational liver associations proposed that metabolic dysfunction-associated steatotic liver disease (MASLD) should replace the term NAFLD; the name chosen to replace non-alcoholic steatohepatitis was metabolic dysfunction-associated steatohepatitis (MASH). Emerging epidemiological evidence suggests an excellent concordance rate between NAFLD and MASLD definitions—that is, ~99% of individuals with NAFLD meet MASLD criteria. In this narrative review, we provide an overview of the literature on (a) the recent epidemiological data on MASLD and the risk of developing CVD and malignant complications, (b) the underlying mechanisms by which MASLD (and factors strongly linked with MASLD) may increase the risk of these extrahepatic complications and (c) the diagnosis and assessment of CVD risk and potential treatments to reduce CVD risk in people with MASLD or MASH.
Subfields: Endocrinology, Diabetes and Metabolism, Epidemiology, Pathology and Forensic Medicine
View Paper: https://www.semanticscholar.org/paper/5136ef118e4e0b074b2fc92d40e0e5b78ad593e0
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Endocrinology, Diabetes and Metabolism
In Epidemiology
In Pathology and Forensic Medicine
Citations in the corpus
- Epidemiology of metabolic dysfunction-associated steatotic liver disease (2024, background): “[75] In this case, it appears that the ectopic fat deposition that occurs as MASLD develops also occurs in the epicardium.”